Airway Therapeutics Receives European Medicines Agency Pediatric Committee Approval for Zelpultide Alfa's Study Plan in Bronchopulmonary Dysplasia for Very Preterm Infants
MARIETTA, Ga., Aug. 12, 2025 /CNW/ -- Airway Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has approved its Pediatric Investigation Plan (PIP) for its investigational biologic, zelpultide alfa, in its initial indication for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants born between 22 and 27 weeks gestational age.
Zelpultide alfa is a first-in-class recombinant human surfactant protein D (rhSP-D) designed to modulate immune responses to reduce inflammation, enhance pathogen clearance, and support surfactant homeostasis for improved lung function.
"We are pleased to have reached agreement with the PDCO on the Pediatric Investigation Plan and pivotal study design for zelpultide alfa, a ground-breaking therapy being developed to prevent BPD in very preterm infants, a highly vulnerable population with no approved preventative treatments," said Dr. Marc Salzberg, Chairman, Chief Executive & Medical Officer of Airway Therapeutics. "This marks a significant milestone in advancing a potential first-in-class preventive therapy to improve outcomes for these fragile infants and address a critical unmet medical need."
The approved PIP includes the design and execution plan for a pivotal Phase 2b/3 clinical trial. The Phase 2b trial will evaluate two different dose levels of zelpultide alfa administered for up to seven days, compared to placebo. Following completion of treatment in 150 patients (50 per arm), one dose will be selected for continuation into Phase 3, during which approximately 216 additional patients will be enrolled. As part of the study, Airway Therapeutics will assess a three-day consecutive BPD evaluation endpoint, which may contribute to the development of improved outcome measures during the studies.
"Bronchopulmonary dysplasia remains one of the most challenging complications in neonatal intensive care, with long-term consequences for respiratory and neurodevelopmental outcomes," said Dr. Daniele De Luca, Principal Investigator of the trial and Professor of Pediatrics (Neonatology) at Paris Saclay University. "Zelpultide alfa represents a novel and scientifically promising approach, grounded in our understanding of immune modulation and tissue injury. This study will allow us to rigorously evaluate its potential to change clinical practice by addressing the root drivers of lung injury in very preterm infants."
Airway Therapeutics plans to submit the PDCO-approved protocol immediately to health authorities in Italy (AIFA), Spain (AEMPS), and Israel (MoH), with the objective of initiating the clinical trial in these countries in late Q3 or Q4 2025. Additional submissions will follow in France, Germany, Belgium, and Poland, along with planned regulatory filings in Argentina, Australia, and the United States.
About Zelpultide Alfa
Zelpultide alfa is a recombinant human surfactant protein D (rhSP-D) precisely engineered to replicate the native protein's full quaternary structure and biological function, incorporating optimized glycosylation through advanced cell line technology.
Its therapeutic activity is driven by three key mechanisms: modulation of immune responses to mitigate excessive inflammation, enhancement of pathogen recognition and clearance, and maintenance of surfactant homeostasis to support pulmonary function. As a versatile biologic platform, zelpultide alfa is being developed for patients across all age groups—from preventing bronchopulmonary dysplasia (BPD) in very preterm infants to treating acute and chronic respiratory, inflammatory and infectious conditions in adults.
Zelpultide alfa's lead indication, BPD prevention, is currently progressing through a pivotal Phase 2b/3 clinical trial, following Phase 1 study that demonstrated a favorable safety and tolerability profile.
About Airway Therapeutics
Airway Therapeutics is a clinical-stage biopharmaceutical company developing a new class of biologic therapies to redefine the prevention and treatment of respiratory, inflammatory, and infectious diseases. Its lead candidate, zelpultide alfa, is currently in late-stage clinical development for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants, a condition with no approved preventive therapies. As a platform biologic, zelpultide alfa is also being advanced for broader application across age groups and disease settings, with the goal of improving outcomes for vulnerable patient populations.
Company Contact:
Libba Muzi
Airway Therapeutics
[email protected]
513-770-9630
Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
[email protected]
212-845-4251
SOURCE Airway Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Young Mother's Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC
VANCOUVER, BC, /CNW/ - Eileen Davidson, a Burnaby mother and advocate, is calling on the BC government to modernize its approach to rheumatoid arthritis (RA) treatment by removing barriers that prevent patients from accessing the medications they truly need—barriers not found in many other provinces. Diagnosed with seropositive rheumatoid arthritis at just 29 years old, Eileen spent years searching for answers while coping with disabling pain, extreme fatigue, and the emotional toll of chronic illness. "By the time I was diagnosed, I was on the verge of being placed on long-term disability," Eileen recalls. "I had a toddler at home and every day was a struggle just to care for him." Forced to Wait While Suffering Like many RA patients in BC, Eileen's path to relief was slowed by a policy known as Step Therapy. Under Step Therapy, patients are required to try and 'fail' on older, less effective medications—sometimes for a year or more—before they can access modern treatments like biologics that offer the best chance for remission. "My doctor and I both knew these medications weren't likely to work for me, but we had no choice," Eileen says. "All that time, my disease kept progressing, and my hope for a normal life was slipping away." Eliminating these treatment delays remains a key priority for Arthritis Society Canada, the national organization leading advocacy, research, and support for the six million Canadians with arthritis. "There is no cure for arthritis. And because arthritis medications often require trial and error to find what works, speed of access is critical in preventing irreversible damage," says Trish Barbato, President and CEO of Arthritis Society Canada. "What works for one person may not work for another, and people often become resistant to treatment over time, making timely access to a range of medications even more essential." Eileen's story is far from unique. Arthritis is the leading cause of disability in North America, affecting people of all ages, and early access to the right treatment is critical. Yet in BC, restrictive policies leave many patients—especially younger adults—facing avoidable disability, work loss, and deteriorating health. A Personal and Systemic Cost The impact goes beyond the individual. Untreated or undertreated RA can lead to irreversible joint damage, increased healthcare use, and higher costs for the system as a whole. "If I'd had access to effective treatment earlier, I might still be working full-time," says Eileen. "Instead, I lost years to pain and fatigue, and my disease progressed much faster than it needed to." MedAccessBC Calls for Policy Change Eileen's experience underscores a larger, systemic issue that the Medicines Access Coalition – BC (MedAccessBC) has been fighting to address for over two decades. "Forcing patients to fail on older medications before approving access to newer, proven treatments is not only out of step with medical evidence—it's unfair and costly in the long run," says Jamie Myrah, Co-Chair of MedAccessBC. "All British Columbians deserve the opportunity for the best possible health outcomes, not arbitrary delays." As a non-profit coalition representing over 30 patient care organizations, MedAccessBC urges the BC government to review and update Step Therapy policies for rheumatoid arthritis and similar chronic conditions, ensuring that treatment decisions prioritize patient well-being and clinical best practices. A Call to Action Eileen's message to policymakers is clear: "Please give people like me a fighting chance to live, work, and participate fully in our communities. Timely access to the right medication isn't a luxury—it's a lifeline." About Rheumatoid Arthritis (RA) Rheumatoid arthritis is an autoimmune disease that causes the body's immune system to attack healthy joints and tissues. It can strike at any age and leads to pain, swelling, and fatigue. If not treated effectively and early, RA can result in severe disability, organ complications, and reduced life expectancy. There are more than 100 types of arthritis and related autoimmune conditions, affecting millions of Canadians. (Arthritis Society Canada) About the Medicines Access Coalition of BC MedAccess BC advocates for improved access to medications and health technologies for individuals with chronic diseases. Representing over 30 patient organizations, it has been working since 1997 to improve access to evidence-based medicines through BC's PharmaCare program. About Arthritis Society Canada Arthritis Society Canada represents the six million people in Canada living with arthritis today, and the millions more who are impacted or at risk. Fueled by the trust and support of our donors and volunteers, Arthritis Society Canada is fighting arthritis with research, advocacy, innovation, information and support. We are Canada's largest charitable funder of cutting-edge arthritis research. We will not give up our efforts until everyone is free from the agony of arthritis. Arthritis Society Canada is accredited under Imagine Canada's Standards Program. For more information, visit
Cision Canada
an hour ago
- Cision Canada
NEVADA KING ANNOUNCES RESULTS OF SHAREHOLDER MEETING AS WELL AS BOARD AND MANAGEMENT CHANGES
VANCOUVER, BC, Aug. 14, 2025 /CNW/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQB: NKGFF) (" Nevada King" or the " Company") is pleased to announce that, at its meeting of Shareholders (the " Shareholders") held today, August 14, 2025, Shareholders approved the re-election of Collin Kettell and William Hayden to the Board of Directors (the " Board") of the Company . In addition, John Sclodnick and Michael Doolin were elected to the Board. Former directors Paul Matysek and Craig Roberts did not stand for re-election. Effective immediately, Mr. Sclodnick will serve as the Company's Chief Executive Officer replacing Collin Kettell, who remains a Director of the Company. Mr. Kettell was appointed Chairman on the date hereof. In addition, the Company announces the appointment of Jeff Stieber as the Company's Chief Financial Officer, following the resignation of Bassam Moubarak. "On behalf of the company, I'd like to thank Paul Matysek, Craig Roberts, and Bassam Moubarak for their significant contributions since inception. We wish them all every success in their future endeavours", stated Mr. Kettell. "I am also pleased to welcome Jeff Stieber, whose senior leadership experience across exploration, development, and production stages will be invaluable as we advance our Atlanta project, and I'm excited to see John Sclodnick take over the role as CEO of the Company. Over the past year, working closely with John has strengthened my confidence in his leadership, which has already helped drive increased institutional ownership. As Founder and Chairman, I am confident the Company is on a strong path forward under his guidance and I look forward to working in tandem with him to advance Nevada King." Mr. Sclodnick, CEO stated: "It is an exciting time for Nevada King, with exploration momentum building across a number of highly prospective targets at our Atlanta project, to complement our high-grade and high-confidence resource. I'm eager to continue to build that momentum alongside our dedicated and energized team, to advance these targets, generate significant discoveries, and create real value for our shareholders." All other matters put forward before the Shareholders at the meeting for consideration and approval, including the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditor of the Company at a remuneration to be fixed by the Board, and renewal of the stock option plan of the Company, as set out in the Company's Management Information Circular dated July 4, 2025, were approved. With more than 35 years of experience in the mining industry, Mr. Doolin has led various companies in driving operational efficiency. At Karora Resources Inc., he served as Senior Vice President of Technical Services and was a key player in increasing the company's throughput from 340,000 to 1.6 million tonnes per annum, which was a significant factor in its successful merger. In his capacity as Chief Operating Officer of Klondex Mines Ltd., he played a crucial role in raising gold production from 8,000 to 200,000 ounces per year, which contributed to the company's acquisition by Hecla Mining Company. Mr. Doolin has also held Chief Executive and Chief Operating Officer positions at Silver Elephant Mining, as well as leadership roles as Mill Manager at Great Basin Gold and Metallurgical Lab Lead at McClelland Labs. He currently serves as Chief Operating Officer of Americas Gold and Silver Corporation and Culico Metals Inc. Jeff Stieber Mr. Stieber has over 19 years of experience in finance, accounting, and strategy, having held senior executive roles with Hycroft Mining, Klondex Mines, Tahoe Resources, White Pine Precious Metals, and Bendito Resources. He is knowledgeable in all phases of mining project development, from guiding exploration-stage projects to advancing development assets into production and cash flow generation. Mr. Stieber is a Certified Public Accountant in the State of Nevada and a Certified Financial Modeling & Valuation Analyst. He also currently serves as a director for Chesapeake Gold Corp. About Nevada King Gold Corp. Nevada King is focused on advancing and growing its 100% owned, past producing, 130km 2 Atlanta Gold Mine project located along the Battle Mountain trend in southeast Nevada. The project hosts an NI 43-101 compliant pit-constrained oxide resource of 1,020koz Au in the measured and indicated category (27.7M tonnes at 1.14 g/t) plus an inferred resource of 99koz Au (3.6M tonnes at 0.84 g/t). See the NI 43-101 Technical Report titled "Technical Report and Estimate of Gold and Silver Mineral Resources for the Atlanta Project, Lincoln County, Nevada, USA" with an effective date of September 6, 2024, and a report date of July 18, 2025, as prepared by RESPEC (formerly Mine Development Associates) and filed under the Company's profile on SEDAR+ NI 43-101 Mineral Resources at the Atlanta Mine by RESPEC 2025 Please see the Company's website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statements Regarding Forward Looking Information This news release contains certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operations and activities of Nevada King, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or" should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by Nevada King, are inherently subject to significant business, economic, technical, geologic, environmental, regulatory, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability to complete proposed exploration work, the results of exploration, continued availability of capital, and changes in general economic, market and business conditions. Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these items. Nevada King does not assume any obligation to update forward-looking statements should beliefs, opinions, projections, or other factors, change, except as required by applicable securities laws. SOURCE Nevada King Gold Corp.
Cision Canada
an hour ago
- Cision Canada
Various brands of Pistachio & Knafeh Milk Chocolate recalled due to Salmonella
OTTAWA, ON, Aug. 14, 2025 /CNW/ - Product: Pistachio & Knafeh Milk Chocolate Issue: Food - Microbial contamination - Salmonella Distribution: Online British Columbia Ontario Quebec See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)
